1. Lazarus, R. S. Patterns of Adjustment, 3rd edn. McGraw Hill, New York, 1966.Freud, S. A General Introduction to Psychoanalysis. Boni & Liveright, New York, 1920.
2. Auerbach, S. M. Trait-state anxiety and adjustment to surgery. J. Consult Clin. Psychol. 1973; 40: 264- 271. 32.
3. Dobson, K. S. An analysis of anxiety and depression scales. J. Pers. Assess. 1985; 49: 522-527.
4. Elke Humer et al.,2020
5. Ceylan, M.F.; Guney, E.; Alisik, M.; Ergin, M.; Dinc, G.S.; Goker, Z.; Eker, S.; Kizilgun, M.; Erel, O. Lipid peroxidation markers in children with anxiety disorders and their diagnostic implications. Redox Rep. 2014, 19, 92–96. [CrossRef] [PubMed]
6. Jalnapurkar, I.; Allen, M.; Pigott, T. Sex differences in anxiety disorders: A review. Pda J. Pharmacol. Sci. Technol. 2018, 4, 1–9. [CrossRef] What happens to anxiety disorders in later life? Rev. Bras. Psiquiatr. 2002, 24, 74–80. [CrossRef]
7. Shadli, S.M.; McIntosh, J.; McNaughton, N. Anxiety process “theta” biomarker in the stop signal task eliminated by a preceding relaxation test. Behav. Neurosci. 2020, in press. [CrossRef] [PubMed]
8. Olatunji, B.O.; Cisler, J.M.; Deacon, B.J. Efficacy of cognitive behavioral therapy for anxiety disorders: A review of meta-analytic findings. Psychiatr. Clin. N. Am. 2010, 33, 557–577. [CrossRef]
9. Loerinc, A.G.; Meuret, A.E.; Twohig, M.P.; Rosenfield, D.; Bluett, E.J.; Craske, M.G. Response rates for CBT for anxiety disorders: Need for standardized criteria. Clin. Psychol. Rev. 2015, 42, 72–82. [CrossRef] [PubMed]
10. Kapur, S.; Phillips, A.G.; Insel, T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol. Psychiatry 2012, 17, 1174–1179. [CrossRef] [PubMed].
11. Schneider, R.L.; Arch, J.J.; Wolitzky-Taylor, K.B. The state of personalized treatment for anxiety disorders: A systematic review of treatment moderators. Clin. Psychol. Rev. 2015, 38, 39–54. [CrossRef].
12. Guest, P.C.; Guest, F.L.; Martins-de Souza, D. Making sense of blood-based proteomics and metabolomics in psychiatric research. IJNPPY 2016, 19, pyv138. [CrossRef]
13. McCarter, G.C.; Blanchard, L.B. Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states. Oxf. Med. Case Rep. 2017, 2017, omx060. [CrossRef] [PubMed]
14. Loas, G.; Dalleau, E.; Lecointe, H.; Yon, V. Relationships between anhedonia, alexithymia, impulsivity, suicidal ideation, recent suicide attempt, C-reactive protein and serum lipid levels among 122 inpatients with mood or anxious disorders. Psychiatry Res. 2016, 246, 296–302. [CrossRef]
15. Toker, S.; Shirom, A.; Shapira, I.; Berliner, S.; Melamed, S. The association between burnout, depression, anxiety, and inflammation biomarkers: C-reactive protein and fibrinogen in men and women. J. Occup. Health Psychol. 2005, 10, 344–362. [CrossRef] [PubMed]
16. Gammoh, O.S.; Al-Smadi, A.M.; Ashour, A.F.; Al-Awaida, W. Salivary nitric oxide, a biomarker for stress and anxiety? Psychiatry Investig. 2016, 13, 311. [CrossRef] [PubMed]
17. Grimes, S.B.; Wild, R. Effect of pregnancy on lipid metabolism and lipoprotein levels. In Endotext [Internet]; MDText.com, Inc.: South Dartmouth, MA, USA, 2018.
18. Graeff, F. G., Guimarães, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996). *Role of 5-HT in stress, anxiety, and depression. Pharmacology Biochemistry and Behavior, 54(1), 129–141.* doi:10.1016/0091-3057(95)02135-3
19. Handley, S. L. (1995). *5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacology & Therapeutics, 66(1), 103–148.* doi:10.1016/0163-7258(95)00004-z
20. Albert PR, Vahid-Ansari F, Luckhart C. Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci. 2014 Jun 6;8:199. doi: 10.3389/fnbeh.2014.00199. PMID: 24936175; PMCID: PMC4047678.
21. Rossi S, Sacchetti L, Napolitano F, De Chiara V, Motta C, Studer V, Musella A, Barbieri F, Bari M, Bernardi G, Maccarrone M, Usiello A, Centonze D. Interleukin-1β causes anxiety by interacting with the endocannabinoid system. J Neurosci. 2012 Oct 3;32(40):13896-905. doi: 10.1523/JNEUROSCI.1515-12.2012. PMID: 23035099; PMCID: PMC6704788.
22. Wang, J.; Jiang, C.; Chen, L.; Wu, S.; Lin, J.; Gao, L.; Xie, B.; Zheng, D.; Yang, R.; Li, S.; et al. A cross-sectional study to investigate the correlation between depression comorbid with anxiety and serum lipid levels. Compr. Psychiatry 2016, 69, 163–168. [CrossRef] [PubMed]
23. Mishra, T.K.; Shankar, R.; Sharma, I.; Srivastava, P.K. Serum lipids in anxiety neurosis. Indian J. Psychiatry 1984, 26, 237–241. [PubMed]
24. Chen, C.-C.; Huang, T.-L. Association of serum lipid profiles with depressive and anxiety disorders in menopausal women. Chang. Gung Med. J. 2006, 29, 325
25. Casares, D.; Escribá, P.V.; Rosselló, C.A. Membrane lipid composition: Effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int. J. Mol. Sci. 2019, 20, 2167. [CrossRef]
26. Müller, C.P.; Reichel, M.; Mühle, C.; Rhein, C.; Gulbins, E.; Kornhuber, J. Brain membrane lipids in major depression and anxiety disorders. Biochim. Biophys. Acta (Bba)—Mol. Cell Biol. Lipids 2015, 1851, 1052–1065. [CrossRef]
27. Postila, P.A.; Róg, T. A perspective: Active role of lipids in neurotransmitter dynamics. Mol. Neurobiol. 2020, 57, 910–925. [CrossRef] [PubMed]
28. Maes, M.; Bonifacio, K.L.; Morelli, N.R.; Vargas, H.O.; Moreira, E.G.; St. Stoyanov, D.; Barbosa, D.S.; Carvalho, A.F.; Nunes, S.O.V. Generalized anxiety disorder (GAD) and comorbid major depression with GAD are characterized by enhanced nitro-oxidative stress, increased lipid peroxidation, and lowered lipid-associated antioxidant defenses. Neurotox Res. 2018, 34, 489–510. [CrossRef] [PubMed]
29. Gammoh, O.S.; Al-Smadi, A.M.; Ashour, A.F.; Al-Awaida, W. Salivary nitric oxide, a biomarker for stress and anxiety? Psychiatry Investig. 2016, 13, 311. [CrossRef] [PubMed]
30. Jin, L.; Qin, L.; Xia, D.; Liu, X.; Fan, Z.; Zhang, C.; Gu, L.; He, J.; Ambudkar, I.S.; Deng, D.; et al. Active secretion and protective effect of salivary nitrate against stress in human volunteers and rats. Free Radic. Biol. Med. 2013, 57, 61–67. [CrossRef]
31. Ceylan, M.F.; Guney, E.; Alisik, M.; Ergin, M.; Dinc, G.S.; Goker, Z.; Eker, S.; Kizilgun, M.; Erel, O. Lipid peroxidation markers in children with anxiety disorders and their diagnostic implications. Redox Rep. 2014, 19, 92–96. [CrossRef] [PubMed]
32. Brites, F.; Martin, M.; Guillas, I.; Kontush, A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. Bba Clin. 2017, 8, 66–77. [CrossRef]
33. Bulut, M.; Selek, S.; Bez, Y.; Karababa, I.F.; Kaya, M.C.; Gunes, M.; Emhan, A.; Aksoy, N.; Sir, A. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J. Affect. Disord. 2013, 150, 829–833. [CrossRef]
34. Petrakova, L.; Boy, K.; Mittmann, L.; Möller, L.; Engler, H.; Schedlowski, M. Salivary alpha-amylase and noradrenaline responses to corticotropin-releasing hormone administration in humans. Biol. Psychol. 2017, 127, 34–39. [CrossRef]
35. Jafari, A.; Pouramir, M.; Shirzad, A.; Motallebnejad, M.; Bijani, A.; Moudi, S.; Abolghasem-Zade, F.; Dastan, Z. Evaluation of salivary alpha amylase as a biomarker for dental anxiety. Iran. J. Psychiatry Behav. Sci. 2018, 12, e9350. [CrossRef]
36. Denes, V.; Geck, P.; Mester, A.; Gabriel, R. Pituitary adenylate cyclase-activating polypeptide: 30 years in research spotlight and 600 million years in service. JCM 2019, 8, 1488. [CrossRef] [PubMed]
37. Ross, R.A.; Hoeppner, S.S.; Hellberg, S.N.; O’Day, E.B.; Rosencrans, P.L.; Ressler, K.J.; May, V.; Simon, N.M. Circulating PACAP peptide and PAC1R genotype as possible transdiagnostic biomarkers for anxiety disorders in women: A preliminary study. Neuropsychopharmacology 2020, 45, 1125–1133. [CrossRef] [PubMed]
38. Graham, B.M.; Richardson, R. Memory of fearful events: The role of fibroblast growth factor-2 in fear acquisition and extinction. Neuroscience 2011, 189, 156–169. [CrossRef]
39. Graham, B.M. Fibroblast growth factor-2: A promising biomarker for anxiety and trauma disorders. J. Exp. Neurosci. 2017, 11, 117906951774958. [CrossRef]
40. Hill, M.; Dušková, M.; Stárka, L. Dehydroepiandrosterone, its metabolites and ion channels. J. Steroid Biochem. Mol. Biol. 2015, 145, 293–314. [CrossRef] [PubMed]
41. Jung, Y.-H.; Kim, H.; Jeon, S.Y.; Kwon, J.M.; Lee, W.J.; Jang, J.H.; Lee, D.; Lee, Y.; Kang, D.-H. Peripheral and central metabolites affecting depression, anxiety, suicidal ideation, and anger in complex regional pain syndrome patients using a magnetic resonance spectroscopy: A pilot study. Psychiatry Investig. 2018, 15, 891–899. [CrossRef] [PubMed]